Endothelial progenitor cells and cardiovascular cell-based therapies

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Since their initial discovery more than a decade ago, bone marrow (BM)-derived circulating endothelial progenitor cells (EPC) have been reported to play a role in postnatal vasculogenesis through vessel regeneration and remodeling. These cells have been reported to mobilize into the blood stream in response to vascular injury, and differentiate into cells expressing a host of endothelial cell (EC) markers in vitro. Because of demonstrable regenerative capacity in animal models of human disease, EPC are thought to represent a novel treatment option for problematic cardiovascular conditions such as myocardial infarction (MI) and peripheral vascular disease (PVD). Various studies have been performed to test the clinical efficacy of EPC in patients with cardiovascular disease (CVD), including the mobilization of EPC with pharmacologic agents in patients with heart disease, and harvesting of cells from the circulation and BM for autologous reinfusion in affected patients. The outcomes of these trials have been mixed and not as robust as predicted from the animal models, partly because of the variation in the definition of human EPC and the resulting heterogeneity in cell populations used in the treatments. This review will decipher a number of published studies that have been conducted to examine cell therapies for treatment of CVD, will attempt to explain why efficacy of treatment with putative EPC has been inconsistent, and predict which aspects of these trials may need to be redesigned for future successful treatment of CVD.

Original languageEnglish
Pages (from-to)103-113
Number of pages11
JournalCytotherapy
Volume11
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Cell- and Tissue-Based Therapy
Cardiovascular Diseases
Animal Disease Models
Peripheral Vascular Diseases
Vascular System Injuries
Proxy
Therapeutics
Bone Marrow Cells
Endothelial Progenitor Cells
Regeneration
Heart Diseases
Endothelial Cells
Animal Models
Bone Marrow
Myocardial Infarction
Population

Keywords

  • Cardiovascular disease
  • Endothelial progenitor cell
  • Myocardial infarction

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Molecular Medicine

Cite this

Endothelial progenitor cells and cardiovascular cell-based therapies. / Mund, Julie A.; Ingram, David; Yoder, Mervin; Case, Jamie.

In: Cytotherapy, Vol. 11, No. 2, 2009, p. 103-113.

Research output: Contribution to journalArticle

@article{03ab1f00e4f44e08b73d196518f54dd0,
title = "Endothelial progenitor cells and cardiovascular cell-based therapies",
abstract = "Since their initial discovery more than a decade ago, bone marrow (BM)-derived circulating endothelial progenitor cells (EPC) have been reported to play a role in postnatal vasculogenesis through vessel regeneration and remodeling. These cells have been reported to mobilize into the blood stream in response to vascular injury, and differentiate into cells expressing a host of endothelial cell (EC) markers in vitro. Because of demonstrable regenerative capacity in animal models of human disease, EPC are thought to represent a novel treatment option for problematic cardiovascular conditions such as myocardial infarction (MI) and peripheral vascular disease (PVD). Various studies have been performed to test the clinical efficacy of EPC in patients with cardiovascular disease (CVD), including the mobilization of EPC with pharmacologic agents in patients with heart disease, and harvesting of cells from the circulation and BM for autologous reinfusion in affected patients. The outcomes of these trials have been mixed and not as robust as predicted from the animal models, partly because of the variation in the definition of human EPC and the resulting heterogeneity in cell populations used in the treatments. This review will decipher a number of published studies that have been conducted to examine cell therapies for treatment of CVD, will attempt to explain why efficacy of treatment with putative EPC has been inconsistent, and predict which aspects of these trials may need to be redesigned for future successful treatment of CVD.",
keywords = "Cardiovascular disease, Endothelial progenitor cell, Myocardial infarction",
author = "Mund, {Julie A.} and David Ingram and Mervin Yoder and Jamie Case",
year = "2009",
doi = "10.1080/14653240802714827",
language = "English",
volume = "11",
pages = "103--113",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Endothelial progenitor cells and cardiovascular cell-based therapies

AU - Mund, Julie A.

AU - Ingram, David

AU - Yoder, Mervin

AU - Case, Jamie

PY - 2009

Y1 - 2009

N2 - Since their initial discovery more than a decade ago, bone marrow (BM)-derived circulating endothelial progenitor cells (EPC) have been reported to play a role in postnatal vasculogenesis through vessel regeneration and remodeling. These cells have been reported to mobilize into the blood stream in response to vascular injury, and differentiate into cells expressing a host of endothelial cell (EC) markers in vitro. Because of demonstrable regenerative capacity in animal models of human disease, EPC are thought to represent a novel treatment option for problematic cardiovascular conditions such as myocardial infarction (MI) and peripheral vascular disease (PVD). Various studies have been performed to test the clinical efficacy of EPC in patients with cardiovascular disease (CVD), including the mobilization of EPC with pharmacologic agents in patients with heart disease, and harvesting of cells from the circulation and BM for autologous reinfusion in affected patients. The outcomes of these trials have been mixed and not as robust as predicted from the animal models, partly because of the variation in the definition of human EPC and the resulting heterogeneity in cell populations used in the treatments. This review will decipher a number of published studies that have been conducted to examine cell therapies for treatment of CVD, will attempt to explain why efficacy of treatment with putative EPC has been inconsistent, and predict which aspects of these trials may need to be redesigned for future successful treatment of CVD.

AB - Since their initial discovery more than a decade ago, bone marrow (BM)-derived circulating endothelial progenitor cells (EPC) have been reported to play a role in postnatal vasculogenesis through vessel regeneration and remodeling. These cells have been reported to mobilize into the blood stream in response to vascular injury, and differentiate into cells expressing a host of endothelial cell (EC) markers in vitro. Because of demonstrable regenerative capacity in animal models of human disease, EPC are thought to represent a novel treatment option for problematic cardiovascular conditions such as myocardial infarction (MI) and peripheral vascular disease (PVD). Various studies have been performed to test the clinical efficacy of EPC in patients with cardiovascular disease (CVD), including the mobilization of EPC with pharmacologic agents in patients with heart disease, and harvesting of cells from the circulation and BM for autologous reinfusion in affected patients. The outcomes of these trials have been mixed and not as robust as predicted from the animal models, partly because of the variation in the definition of human EPC and the resulting heterogeneity in cell populations used in the treatments. This review will decipher a number of published studies that have been conducted to examine cell therapies for treatment of CVD, will attempt to explain why efficacy of treatment with putative EPC has been inconsistent, and predict which aspects of these trials may need to be redesigned for future successful treatment of CVD.

KW - Cardiovascular disease

KW - Endothelial progenitor cell

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=68049147002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049147002&partnerID=8YFLogxK

U2 - 10.1080/14653240802714827

DO - 10.1080/14653240802714827

M3 - Article

VL - 11

SP - 103

EP - 113

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 2

ER -